Heart Failure

Heart Failure - 2017 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/244042

Contents of this Issue

Navigation

Page 49 of 61

50 Table 29. Ten Most Common Co-Occurring Chronic Conditions Among Medicare Beneficiaries With HF (N=4,947,918), 2011 Beneficiaries Age ≥65 y (N = 4,376,150) a Beneficiaries Age <65 y (N = 571,768) b N % N % Hypertension 3,685,373 84.2 Hypertension 461,235 80.7 Ischemic heart disease 3,145,718 71.9 Ischemic heart disease 365,889 64.0 Hyperlipidemia 2,623,601 60.0 Diabetes 338,687 59.2 Anemia 2,200,674 50.3 Hyperlipidemia 325,498 56.9 Diabetes 2,027,875 46.3 Anemia 284,102 49.7 Arthritis 1,901,447 43.5 Chronic kidney disease 257,015 45.0 Chronic kidney disease 1,851,812 42.3 Depression 207,082 36.2 COPD 1,311,118 30.0 Arthritis 201,964 35.3 AF 1,247,748 28.5 COPD 191,016 33.4 Alzheimer disease/dementia 1,207,704 27.6 Asthma 88,816 15.5 a Mean number of conditions, 6.1; median, 6. b Mean number of conditions, 5.5; median, 5. Data source: Centers for Medicare & Medicaid Services administrative claims data, January 2011 to December 2011, from the Chronic Condition Warehouse (CCW), ccwdata.org. Other Comorbidities Table 28. Anemia: Recommendations (2017) COR LOE Recommendations IIb B-R In patients with NYHA class II and III HF and iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL if transferrin saturation is <20%), intravenous iron replacement might be reasonable to improve functional status and QoL. III: No Benefit B-R In patients with HF and anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality. Treatment

Articles in this issue

Links on this page

view archives of Heart Failure - Heart Failure - 2017 Update